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Available online 23 June 2016Despite the remarkable improvement in overall survival
of chronic myeloid leukaemia (CML) patients treated with
the tyrosine kinase inhibitor (TKI) imatinib, a significant pro-
portion of patients are intolerant to imatinib requiring a
switch to a second-generation TKI. While the vast majority
of CML patients express either e13a2 or e14a2 BCR-ABL1
transcripts, less than 5% of patients express atypical tran-
script types of which e19a2 is the most frequently encoun-
tered. Responses to first-line imatinib are variable in
e19a2 BCR-ABL1 CML [1,2], possibly confounded due to
the lack of reporting or bias in favour of cases with atypical
features and/or responses. Furthermore, despite several
cases documenting good molecular responses in ABL1 kinase
domain mutation-associated imatinib-resistant e19a2 BCR-
ABL1 CML with the second generation TKIs nilotinib and
dasatinib [3–5], the use of these drugs in imatinib-intoler-
ant CML patients with this atypical genotype is limited.
An asymptomatic 53-year-old woman presented with an
incidental finding of neutrophilia and thrombocytosis. Bonemarrow morphology and cytogenetics confirmed chronic
phase CML with molecular analysis demonstrating e19a2
BCR-ABL1 transcripts. She commenced on 400-mg imatinib
once daily but at 3 months had become neutropenic
(0.67  109/L). Imatinib was stopped for 1 week and granu-
locyte-colony stimulating factor was administered. How-
ever, 1 month later due to ongoing neutropenia and the
continued requirement for granulocyte-colony stimulating
factor, she switched to 400-mg nilotinib twice daily with
the neutropenia resolving quickly. Prospective real-time
quantitative polymerase chain reaction, performed as previ-
ously described [6], demonstrated a decline in the BCR-
ABL1/ABL1 transcript level to less than 0.1% within
18 months of diagnosis (Fig. 1). Despite generalised aches
and pains and ongoing fatigue the patient has tolerated nilo-
tinib well and at the last follow-up 54 months from presen-
tation had a BCR-ABL1/ABL1 level of 0.001% (Fig. 1).
The sustained molecular response observed in the ima-
tinib-intolerant patient described herein confirms the long
term efficacy of nilotinib in imatinib-intolerant e19a2 BCR-
ABL1 CML [7]. Given the increasingly reported favourable
responses to second-line treatment due to ABL1 kinase
domain mutation-associated imatinib resistance [3–5] and
first-line treatment [6,8–10] with nilotinib and dasatinib,
Fig. 1 Molecular monitoring of e19a2 BCR-ABL1/ABL1 transcripts.
Nilotinib in e19a2 CML 169these second-generation TKIs should be earnestly consid-
ered as front-line agents in e19a2 BCR-ABL1 CML patients.
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